Literature DB >> 19519255

Immunogenicity testing in human papillomavirus virus-like-particle vaccine trials.

John T Schiller1, Douglas R Lowy.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19519255      PMCID： PMC3467007          DOI： 10.1086/599988

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


× No keyword cloud information.
  27 in total

1.  Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial.

Authors:  Diane M Harper; Eduardo L Franco; Cosette M Wheeler; Anna-Barbara Moscicki; Barbara Romanowski; Cecilia M Roteli-Martins; David Jenkins; Anne Schuind; Sue Ann Costa Clemens; Gary Dubin
Journal:  Lancet       Date:  2006-04-15       Impact factor: 79.321

2.  Results of the first WHO international collaborative study on the standardization of the detection of antibodies to human papillomaviruses.

Authors:  Morag Ferguson; Alan Heath; Suzanne Johnes; Sonia Pagliusi; Joakim Dillner
Journal:  Int J Cancer       Date:  2006-03-15       Impact factor: 7.396

3.  Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only.

Authors:  Sandra L Giannini; Emmanuel Hanon; Philippe Moris; Marcelle Van Mechelen; Sandra Morel; Francis Dessy; Marc A Fourneau; Brigitte Colau; Joann Suzich; Genevieve Losonksy; Marie-Thérèse Martin; Gary Dubin; Martine A Wettendorff
Journal:  Vaccine       Date:  2006-06-19       Impact factor: 3.641

4.  B lymphocyte activation by human papillomavirus-like particles directly induces Ig class switch recombination via TLR4-MyD88.

Authors:  Rongcun Yang; Francisco Martinez Murillo; Michael J Delannoy; R Lee Blosser; William H Yutzy; Satoshi Uematsu; Kiyoshi Takeda; Shizuo Akira; Raphael P Viscidi; Richard B S Roden
Journal:  J Immunol       Date:  2005-06-15       Impact factor: 5.422

5.  Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18.

Authors:  Diana V Pastrana; Christopher B Buck; Yuk-Ying S Pang; Cynthia D Thompson; Philip E Castle; Peter C FitzGerald; Susanne Krüger Kjaer; Douglas R Lowy; John T Schiller
Journal:  Virology       Date:  2004-04-10       Impact factor: 3.616

6.  Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay.

Authors:  David Opalka; Charles E Lachman; Stefani A MacMullen; Kathrin U Jansen; Judith F Smith; Narendra Chirmule; Mark T Esser
Journal:  Clin Diagn Lab Immunol       Date:  2003-01

7.  Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles.

Authors:  Denise Nardelli-Haefliger; Daniel Wirthner; John T Schiller; Douglas R Lowy; Allan Hildesheim; Françoise Ponci; Pierre De Grandi
Journal:  J Natl Cancer Inst       Date:  2003-08-06       Impact factor: 13.506

8.  Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial.

Authors:  Diane M Harper; Eduardo L Franco; Cosette Wheeler; Daron G Ferris; David Jenkins; Anne Schuind; Toufik Zahaf; Bruce Innis; Paulo Naud; Newton S De Carvalho; Cecilia M Roteli-Martins; Julio Teixeira; Mark M Blatter; Abner P Korn; Wim Quint; Gary Dubin
Journal:  Lancet       Date:  2004 Nov 13-19       Impact factor: 79.321

Review 9.  On natural and artificial vaccinations.

Authors:  Rolf M Zinkernagel
Journal:  Annu Rev Immunol       Date:  2001-12-19       Impact factor: 28.527

Review 10.  The papillomavirus life cycle.

Authors:  John Doorbar
Journal:  J Clin Virol       Date:  2005-03       Impact factor: 3.168
View more
  46 in total

Review 1.  Vaccines to prevent infections by oncoviruses.

Authors:  John T Schiller; Douglas R Lowy
Journal:  Annu Rev Microbiol       Date:  2010       Impact factor: 15.500

2.  Human papillomavirus antibody reference reagents for use in postvaccination surveillance serology.

Authors:  Sara L Bissett; Dianna Wilkinson; Kate I Tettmar; Nicky Jones; Elaine Stanford; Gitika Panicker; Helena Faust; Ray Borrow; Kate Soldan; Elizabeth R Unger; Joakim Dillner; Philip Minor; Simon Beddows
Journal:  Clin Vaccine Immunol       Date:  2012-01-25

3.  A quadrivalent HPV vaccine induces humoral and cellular immune responses in WHIM immunodeficiency syndrome.

Authors:  Alessandra Handisurya; Christina Schellenbacher; Bärbel Reininger; Frieder Koszik; Philipp Vyhnanek; Andreas Heitger; Reinhard Kirnbauer; Elisabeth Förster-Waldl
Journal:  Vaccine       Date:  2010-05-14       Impact factor: 3.641

4.  Immunogenicity of Human Papillomavirus Recombinant Vaccine in Children with CKD.

Authors:  Delphine R Nelson; Alicia M Neu; Alison Abraham; Sandra Amaral; Donald Batisky; Jeffrey J Fadrowski
Journal:  Clin J Am Soc Nephrol       Date:  2016-04-07       Impact factor: 8.237

5.  Do vitamin D levels affect antibody titers produced in response to HPV vaccine?

Authors:  Richard K Zimmerman; Chyongchiou Jeng Lin; Jonathan M Raviotta; Mary Patricia Nowalk
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

6.  Comparison of adaptive and innate immune responses induced by licensed vaccines for Human Papillomavirus.

Authors:  Douglas M Herrin; Emily E Coates; Pamela J Costner; Troy J Kemp; Martha C Nason; Kapil K Saharia; Yuanji Pan; Uzma N Sarwar; Lasonji Holman; Galina Yamshchikov; Richard A Koup; Yuk Ying S Pang; Robert A Seder; John T Schiller; Barney S Graham; Ligia A Pinto; Julie E Ledgerwood
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

7.  Immunogenicity assessment of HPV16/18 vaccine using the glutathione S-transferase L1 multiplex serology assay.

Authors:  Hilary A Robbins; Tim Waterboer; Carolina Porras; Troy J Kemp; Michael Pawlita; Ana Cecilia Rodriguez; Sholom Wacholder; Paula Gonzalez; John T Schiller; Douglas R Lowy; Mark Esser; Katie Matys; Sylviane Poncelet; Rolando Herrero; Allan Hildesheim; Ligia A Pinto; Mahboobeh Safaeian
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 8.  Virus-like particles for the prevention of human papillomavirus-associated malignancies.

Authors:  Joshua W Wang; Richard B S Roden
Journal:  Expert Rev Vaccines       Date:  2013-02       Impact factor: 5.217

9.  Prevalence and risk factors for neutralizing antibodies to human papillomavirus types 16 and 18 in HIV-positive men who have sex with men.

Authors:  Rachna Sharma; Jimmy T Efird; Aung Chein; Elizabeth A Holly; Mel Krajden; J Michael Berry; Teresa M Darragh; Naomi Jay; Joel M Palefsky
Journal:  J Acquir Immune Defic Syndr       Date:  2013-12-15       Impact factor: 3.731

10.  Evaluation of the immunogenicity of the quadrivalent HPV vaccine using 2 versus 3 doses at month 21: An epidemiological surveillance mechanism for alternate vaccination schemes.

Authors:  Mauricio Hernández-Ávila; Leticia Torres-Ibarra; Margaret Stanley; Jorge Salmerón; Aurelio Cruz-Valdez; Nubia Muñoz; Rolando Herrero; Ignacio F Villaseñor-Ruíz; Eduardo Lazcano-Ponce
Journal:  Hum Vaccin Immunother       Date:  2015-07-25       Impact factor: 3.452
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.